Latest Hospitality News

Eumundi Group Limited’s shares have been suspended from ASX trading following Federal Court approval of its acquisition by SEQ Hospitality Group Pty Ltd, marking a pivotal step in the company’s transition.

Eumundi Group's scheme of arrangement has been legally approved, paving the way for SEQ Hospitality Group to acquire all shares at $1.62 each. Trading of Eumundi shares on the ASX is suspended effective immediately, with payment scheduled for mid-February.

The Federal Court of Australia has approved SEQ Hospitality Group’s acquisition of Eumundi Group, setting the stage for a $1.62 per share cash payout to shareholders and imminent suspension of Eumundi’s ASX trading.

Pro Medicus has inked a $53 million, seven-year contract with BayCare to deploy its Visage 7 cloud-based imaging platform across Florida’s largest healthcare system, marking a major step in its North American expansion.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.

Beamtree Holdings appoints Marek Stepniak as CEO, signaling a strategic push in international markets with a strong leadership hand familiar with the company’s growth trajectory.

OncoSil Medical has secured authorization for 120 German hospitals to negotiate funding for its pancreatic cancer treatment device, marking a 43% increase from last year and signaling growing acceptance in Germany’s healthcare system.

Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.

Micro-X announces a strategic pivot towards medical imaging, anchored by a $25 million US government contract to develop a portable Full Body CT scanner, while discontinuing its Argus security operations to streamline costs.

LawFinance Limited has completed a significant debt restructuring, easing financial pressures, but faces ongoing challenges with declining cash collections and uncertain progress on its Trident Health Group initiative.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Oakridge International Limited reports a strong quarterly performance driven by increased contracted orders, strategic partnerships, and technological innovation, positioning the company for sustained growth into 2025.